Canada markets open in 4 hours 18 minutes
  • S&P/TSX

    19,435.98
    -120.22 (-0.61%)
     
  • S&P 500

    4,274.51
    +0.98 (+0.02%)
     
  • DOW

    33,550.27
    -68.63 (-0.20%)
     
  • CAD/USD

    0.7405
    +0.0006 (+0.09%)
     
  • CRUDE OIL

    93.86
    +0.18 (+0.19%)
     
  • Bitcoin CAD

    35,636.93
    +196.37 (+0.55%)
     
  • CMC Crypto 200

    566.97
    +4.32 (+0.77%)
     
  • GOLD FUTURES

    1,891.10
    +0.20 (+0.01%)
     
  • RUSSELL 2000

    1,778.90
    +17.29 (+0.98%)
     
  • 10-Yr Bond

    4.6260
    0.0000 (0.00%)
     
  • NASDAQ futures

    14,715.25
    -23.75 (-0.16%)
     
  • VOLATILITY

    18.24
    +0.02 (+0.11%)
     
  • FTSE

    7,547.80
    -45.42 (-0.60%)
     
  • NIKKEI 225

    31,872.52
    -499.38 (-1.54%)
     
  • CAD/EUR

    0.7039
    +0.0045 (+0.64%)
     

Agilent Announces Enhanced xCELLigence RTCA Software Pro to Support Regulatory Compliance Requirements

SANTA CLARA, Calif., June 06, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of the enhanced xCELLigence RTCA Software Pro Version 2.8, an integrated software package for running and analyzing real-time cell analysis data. This improved version enables Agilent xCELLigence Real-Time Cell Analysis (RTCA) systems in GMP-regulated facilities.

The xCELLigence RTCA Software Pro enables data integrity controls to support regulatory requirements defined in FDA 21 CFR Part 11 and EU GMP Annex 11 for electronic records and electronic signatures, an essential requirement in pharmaceutical and biopharmaceutical manufacturing. New and enhanced features ensure that data and electronic records generated with xCELLigence RTCA systems are trustworthy, authentic, and reliable and meet GMP manufacturing compliance requirements.

The xCELLigence RTCA system provides an essential functional potency assay in cell therapy development, manufacturing, and safety applications. Agilent instrumentation and software, alongside customer user organization controls, enables customers to meet FDA 21 CFR Part 11 and other applicable regulatory requirements. This system empowers customers to meet the demands of cell therapy discovery, process development, and QC-release criteria.

"The addition of compliance features to xCELLigence RTCA Software Pro ensures that Agilent xCELLigence RTCA systems meet the regulatory needs of our valued customers, especially in manufacturing and quality control settings," said Todd Christian, vice president and general manager of Agilent’s Cell Analysis Division. "This bridges the regulatory gap, and reinforces Agilent as a leading cell analysis solutions provider to the pharma and biopharma industries."

Agilent’s key focus is to support customers’ regulatory requirements through our instrumentation and software applications. These solutions for compliant environments support immuno-oncology and cell and gene therapy customers, who are developing key components to address human health concerns, furthering Agilent’s core mission to advance the quality of human life.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230606005547/en/

Contacts

Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com